

Juliana Schwaab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2016274/publications.pdf>

Version: 2024-02-01

37
papers

1,532
citations

331670

21
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

1271
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive mutational profiling in advanced systemic mastocytosis. <i>Blood</i> , 2013, 122, 2460-2466.	1.4	222
2	The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. <i>Annals of Hematology</i> , 2014, 93, 81-88.	1.8	142
3	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	2.7	128
4	Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. <i>Blood</i> , 2017, 130, 137-145.	1.4	97
5	The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. <i>Haematologica</i> , 2017, 102, 1035-1043.	3.5	84
6	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2846-2856.	1.6	82
7	Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. <i>Annals of Hematology</i> , 2015, 94, 233-238.	1.8	74
8	<sc><i>KIT</i></sc> <sc><i>D</i></sc> <sc><i>816</i></sc> <sc><i>V</i></sc> and <sc><i>JAK</i></sc> <sc><i>2</i></sc> <sc><i>V</i></sc> <sc><i>617</i></sc> <sc><i>F</i></sc> mutations are seen recurrently in hypereosinophilia of unknown significance. <i>American Journal of Hematology</i> , 2015, 90, 774-777.	4.1	50
9	Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. <i>Annals of Hematology</i> , 2017, 96, 1463-1470.	1.8	48
10	Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 252-259.	2.8	48
11	Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. <i>Blood</i> , 2015, 126, 2832-2841.	1.4	47
12	Response to tyrosine kinase inhibitors in myeloid neoplasms associated with <sc><i>PCM1</i></sc> <sc><i>JAK2</i></sc>, <sc><i>BCR</i></sc> <sc><i>JAK2</i></sc> and <sc><i>ETV6</i></sc> <sc><i>ABL1</i></sc> fusion genes. <i>American Journal of Hematology</i> , 2020, 95, 824-833.	1.1	46
13	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	3.8	42
14	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	4.6	39
15	Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1195-1205.	7.2	38
16	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	3.8	35
17	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2139-2144.	3.8	31
18	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1124-1134.	7.2	29

#	ARTICLE	IF	CITATIONS
19	Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3121-3127.e1.	3.8	28
20	Treatment-free remission in FIP1L1-PDGFR α -positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. <i>Blood Advances</i> , 2020, 4, 440-443.	5.2	27
21	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1783-1794.	1.6	24
22	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306.	2.9	23
23	Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. <i>European Journal of Clinical Investigation</i> , 2016, 46, 392-397.	3.4	21
24	Identification of a leukemia-initiating stem cell in human mast cell leukemia. <i>Leukemia</i> , 2019, 33, 2673-2684.	7.2	21
25	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 411.	4.1	21
26	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1953-1963.	3.8	20
27	An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 945-951.	2.5	14
28	Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis. <i>Annals of Hematology</i> , 2019, 98, 2693-2701.	1.8	11
29	Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (<i>JAK2</i> V617F) and KIT proto-oncogene, receptor tyrosine kinase (<i>KIT</i> D816V) mutations. <i>British Journal of Haematology</i> , 2021, 194, 344-354.	2.5	10
30	Adverse Prognostic Impact of the <i>KIT</i> D816V Transcriptional Activity in Advanced Systemic Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2562.	4.1	9
31	Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. <i>Annals of Hematology</i> , 2022, 101, 1825-1834.	1.8	7
32	Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 817-817.	1.4	6
33	Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 314-318.	1.0	5
34	Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 148, 331.	2.5	2
35	A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients. <i>Blood</i> , 2018, 132, 349-349.	1.4	1
36	Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies <i>KIT</i> D816V As a Distinct and Late Event. <i>Blood</i> , 2014, 124, 3216-3216.	1.4	0

#	ARTICLE	IF	CITATIONS
37	An Increased Bone Mineral Density As an Adverse Prognostic Factor in Patients with Systemic Mastocytosis. Blood, 2019, 134, 4185-4185.	1.4	0